317 related articles for article (PubMed ID: 25468910)
1. Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry.
Ward MD; Leahy DJ
J Biol Chem; 2015 Jan; 290(3):1570-9. PubMed ID: 25468910
[TBL] [Abstract][Full Text] [Related]
2. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
3. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.
Muthuswamy SK; Gilman M; Brugge JS
Mol Cell Biol; 1999 Oct; 19(10):6845-57. PubMed ID: 10490623
[TBL] [Abstract][Full Text] [Related]
4. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging.
Macdonald-Obermann JL; Piwnica-Worms D; Pike LJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):137-42. PubMed ID: 22190492
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
6. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
7. A single ligand is sufficient to activate EGFR dimers.
Liu P; Cleveland TE; Bouyain S; Byrne PO; Longo PA; Leahy DJ
Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10861-6. PubMed ID: 22699492
[TBL] [Abstract][Full Text] [Related]
8. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.
Stortelers C; van De Poll ML; Lenferink AE; Gadellaa MM; van Zoelen C; van Zoelen EJ
Biochemistry; 2002 Apr; 41(13):4292-301. PubMed ID: 11914075
[TBL] [Abstract][Full Text] [Related]
10. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
12. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
Monsey J; Shen W; Schlesinger P; Bose R
J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
[TBL] [Abstract][Full Text] [Related]
13. The single transmembrane domains of ErbB receptors self-associate in cell membranes.
Mendrola JM; Berger MB; King MC; Lemmon MA
J Biol Chem; 2002 Feb; 277(7):4704-12. PubMed ID: 11741943
[TBL] [Abstract][Full Text] [Related]
14. EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity.
Fan YX; Wong L; Johnson GR
Biochem J; 2005 Dec; 392(Pt 3):417-23. PubMed ID: 16122376
[TBL] [Abstract][Full Text] [Related]
15. Ligand discrimination in signaling through an ErbB4 receptor homodimer.
Sweeney C; Lai C; Riese DJ; Diamonti AJ; Cantley LC; Carraway KL
J Biol Chem; 2000 Jun; 275(26):19803-7. PubMed ID: 10867024
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of the effect of ErbB2 on epidermal growth factor receptor binding and dimerization.
Li Y; Macdonald-Obermann J; Westfall C; Piwnica-Worms D; Pike LJ
J Biol Chem; 2012 Sep; 287(37):31116-25. PubMed ID: 22822073
[TBL] [Abstract][Full Text] [Related]
17. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.
Bouyain S; Longo PA; Li S; Ferguson KM; Leahy DJ
Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15024-9. PubMed ID: 16203964
[TBL] [Abstract][Full Text] [Related]
18. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
19. Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation.
Macdonald-Obermann JL; Pike LJ
J Biol Chem; 2014 Sep; 289(38):26178-26188. PubMed ID: 25086039
[TBL] [Abstract][Full Text] [Related]
20. Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins.
Schmidt M; Wels W
Int J Cancer; 2002 Jan; 97(3):349-56. PubMed ID: 11774287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
